Miyashita et al. (http://www.med.kitasato-u.ac.jp/∼molgen/sub10.html) genotyped a panel of Gorlin syndrome patients, finding PTCH1 mutations within various percentages of the patient group: 52.4% were frameshift, 14.3% were nonsense, 11.1% were splicing, and 9.5% were missense mutations. This evidence concerns the gene PTCH1 and nevoid basal cell carcinoma syndrome.